Quantcast
Last updated on April 17, 2014 at 12:30 EDT

Latest Cancer treatments Stories

2013-11-15 23:24:24

Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new protein that kills tumor stem cells. New York, NY (PRWEB) November 15, 2013 Voices Against Brain Cancer, an organization dedicated to brain cancer research and advocacy, comments on a new protein that may become a vital factor in future brain cancer treatments. According to an October 18th, 2013 article published by the Deccan Chronicle titled “Scientist finds new protein to...

2013-11-13 13:23:44

Phase III trial examines pathological complete response rate Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from Aman Buzdar M.D., professor and vice president of clinical research at The University of Texas MD Anderson Cancer Center, and colleagues in the Alliance for Clinical Trials in Oncology, shows these...

2013-11-08 23:04:39

A new study just published online in The Oncologist shows that outpatients receiving chemotherapy are at high risk of developing venous thromboembolism (VTE) and of major bleeding complications, especially those with pancreas, stomach and lung cancer. The authors therefore conclude that thromboprophylaxis, or blood thinning treatments, should be considered for such patients, after carefully assessing the risks and benefits of treatment. Durham, NC (PRWEB) November 08, 2013 A large-scale...

2013-11-08 08:27:45

SEATTLE, Nov. 8, 2013 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of preliminary results from an ongoing Phase 1 trial of ONT-10, a therapeutic vaccine targeting the tumor-associated antigen MUC1, at the Annual Meeting of the Society for Immunotherapy of Cancer in National Harbor, Maryland. The trial is a first-in-man dose escalation trial in patients with advanced, previously treated malignancies of types associated with the expression of MUC1....

2013-11-08 08:25:30

NYU's Dr. Marc Siegel Discusses DCVax And Its Life-Extending Potential As A Cancer Therapy BETHESDA, Md., Nov. 8, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)(NW Bio), a biotechnology company developing non-toxic DCVax(®) personalized immune therapies for solid tumor cancers, announced today that their vaccine was featured yesterday in news coverage on both Fox News and Fox Business News. (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO) The...

2013-11-07 12:28:51

CHARLOTTESVILLE, Va., Nov. 7, 2013 /PRNewswire/ -- Safer and more effective anticancer drugs may soon be developed thanks to a Small Business Innovation Research contract recently awarded to HemoShear by the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH). HemoShear, LLC, is the pharmaceutical industry's leading developer of the most advanced human biology systems for applications in drug research and development. (Logo:...

2013-11-06 08:30:00

SYDNEY, Nov. 6, 2013 /PRNewswire/ -- Novogen Limited (Australian Securities Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated to developing drugs that provide long-term remission through the successful control of cancer stem cells, today announced a joint venture with Yale University dedicated to developing personalized approaches to chemotherapy to fight ovarian cancer. The joint venture, which will be based near Yale's campus in New Haven, CT, will be...

2013-11-05 10:55:56

Study confirms that vascular normalization is the way these drugs improve patient survival Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with anti-angiogenic drugs and which will not. In patients newly diagnosed with the dangerous brain tumor glioblastoma, Massachusetts General Hospital (MGH) researchers report, those for whom treatment with the anti-angiogenic drug cediranib rapidly 'normalized' abnormal blood vessels around their...

2013-11-05 08:34:44

Current Medical Research & Opinion Publishes Positive Decision Impact Study Demonstrating Significant Impact on Colon Cancer Treatment Recommendations REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Current Medical Research & Opinion (CMRO) published positive results from the Partnership for Health Analytic Research (PHAR) clinical utility analysis of the Oncotype DX(®) colon cancer test, demonstrating that use of the...

2013-11-04 08:27:39

TUBINGEN, Germany, and NEW YORK, Nov. 4, 2013 /PRNewswire/ -- The non-profit Cancer Research Institute (CRI) and Ludwig Cancer Research (Ludwig), and CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that they will collaborate to enable clinical testing of novel cancer immunotherapy treatment options. Amplifying the immune system's ability to recognize, attack,...